Medical Oncology Department, Kayseri Education and Research Hospital, Kayseri, Turkey.
Clin Appl Thromb Hemost. 2012 Sep;18(5):546-8. doi: 10.1177/1076029611430958. Epub 2011 Dec 26.
The risk of thromboemboli is increased in patients with cancer, and this is precipitated by the chemotherapeutic agents. Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody and has an importance in the treatment of metastatic colon cancer. The association between bevacizumab, which is demonstrated to increase the risk of thromboemboli, and mean platelet volume (MPV), which is a marker of thrombocyte function, has been investigated within study. A total of 74 patients with metastatic colon cancer were included in the study and the levels of platelets (PLTs), MPV, and platecrit (PCT) values were recorded in SPSS 16.0 program both at baseline and at the >third month. There were significant decreases in 3 parameters (PLT, MPV, and PCT) during the treatment period with bevacizumab (P = .009, P = .001, and P = .000, respectively). Unlike cases with thrombosis, there is a significant decrease in MPV in combination treatments with bevacizumab.
癌症患者发生血栓栓塞的风险增加，这是由化疗药物引起的。贝伐珠单抗是一种抗血管内皮生长因子的单克隆抗体，在转移性结直肠癌的治疗中具有重要作用。研究中已经探讨了贝伐珠单抗（已证实会增加血栓栓塞的风险）与血小板平均体积（MPV）之间的关系，MPV 是血小板功能的标志物。共有 74 例转移性结直肠癌患者纳入研究，在基线和 >第三个月时在 SPSS 16.0 程序中记录血小板（PLT）、MPV 和血小板压积（PCT）值。在贝伐珠单抗治疗期间，这 3 个参数（PLT、MPV 和 PCT）均显著下降（P =.009、P =.001 和 P =.000，分别）。与血栓形成病例不同，在联合使用贝伐珠单抗治疗时，MPV 显著下降。
